 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456» |
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_537;
Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_520;
With binary regression analysis, the only factor significantly associated to delayed administration was a previous two-drugs regimen before switch (OR 0.32, 95% CI 0.129-0.792, p=0.014). Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_519;
With binary regression analysis, the only factor significantly associated to delayed administration was a previous two-drugs regimen before switch (OR 0.32, 95% CI 0.129-0.792, p=0.014). Conclusions :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_510;
Conclusions : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_509;
Purpose : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_506;
Purpose : Purpose :
- Vocabria (cabotegravir oral) / ViiV Healthcare
Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_505;
Purpose : Purpose :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_460;
Purpose : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_459;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_440;
Conclusions : Conclusions :
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_439;
Conclusions : Conclusions :
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy. (Pubmed Central) - Sep 23, 2023
All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) - Sep 13, 2023
P=N/A, N=100, Recruiting, Sponsor: University of Arkansas
iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy. Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: results from the Dutch ATHENA national observational cohort (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_294;
Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024 Purpose :
- bictegravir (GS-9883) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Vemlidy (tenofovir alafenamide) / Gilead
Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: preliminary analysis on cabotegravir plus rilpivirine (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_293;
The vast majority of participants switched from an integrase strand transfer inhibitor-based regimen, with a high proportion having prior exposure to RPV. CAB+RPV-LA discontinuation and confirmed virological failure (0.4?????%) were low.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Failure following switch from long-term suppressive oral ART to long-acting cabotegravir/rilpivirine injections (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_292;
CAB+RPV-LA discontinuation and confirmed virological failure (0.4?????%) were low. Conclusions :
- Vocabria (cabotegravir oral) / ViiV Healthcare, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir-rilpivirine long acting: data in real life setting in a large French cohort (ePosters area) - Sep 10, 2023 - Abstract #EACS2023EACS_263;
Treatment interruption for VR was rare (0.5%) and analysis of emerging resistance at VR is ongoing. A prolonged follow-up is needed to confirm long term efficacy and tolerability.
- Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2998;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2997;
- Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2982;
- Real-World Outcomes with Cabotegravir/Rilpivirine: Does Duration of Pre-treatment Viral Suppression Matter? (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2979;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Weight Change among People Living with HIV who switch from Oral Antiviral Therapy to Long Acting Injectable Cabotegravir/Rilpivirine in a University-Based Clinic (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2978;
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2977;
- The Annual Cost per Newly Virally-Suppressed Person with HIV in Those Starting Long-Acting Injectable Antiretroviral Therapy with Detectable Viremia in a Safety-Net Clinic in San Francisco (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2975;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2957;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB) (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2952;
- Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1355;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1354;
- Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1353;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study (252 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1351;
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. (Pubmed Central) - Aug 16, 2023
The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial initiation date: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov) - Aug 16, 2023
P1/2, N=90, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting. Initiation date: Jul 2023 --> Oct 2023
- | Edurant (rilpivirine) / J&J, Sublocade (buprenorphine once-monthly depot) / Indivior, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P1 trial, Adherence: CHOICE: Combined Injectable Treatment for HIV and OUD (clinicaltrials.gov) - Aug 14, 2023
P1, N=40, Recruiting, Sponsor: Rhode Island Hospital
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Immune Reconstitution Inflammatory Syndrome in Aids Patient After Successful Induction of Virological Suppression with Cabotegravir/Rilpivirine. (Pubmed Central) - Aug 9, 2023
CAB/RPV has no activity against HBV, which may have contributed to its reactivation.The patient had serologic evidence of resolution of prior HBV. However, some patients have covalently closed circular DNA (cccDNA) that may remain long term in hepatocyte nuclei.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States. (Pubmed Central) - Jul 31, 2023
The approval of long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) heightened the urgency of ensuring effective implementation...There is variability of readiness yet high levels of perceived acceptability and appropriateness of implementing LAI CAB/RPV among Ryan White clinics, necessitating tailored interventions for successful implementation. A special focus on addressing the barriers of adherence and the cost of implementation is needed.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 (Pubmed Central) - Jul 15, 2023
P3
A special focus on addressing the barriers of adherence and the cost of implementation is needed. From the Spanish National Health System perspective, CAB+RPV LA Q2M is a cost-effective alternative compared with the current options of daily oral STR regimens for HIV treatment.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV. (Pubmed Central) - Jul 3, 2023
Further data on the ability of LA-ART to achieve viral suppression in people with barriers to adherence are needed. National Institutes of Health, City and County of San Francisco, and Health Resources and Services Administration.
- |||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
These findings offer reassurance that people with #HIV who start or switch to modern integrase inhibitor antiretroviral regimens, including Biktarvy or Cabenuva, can keep the virus under control for years. @PaulSaxMD @overton_edgar https://t.co/KLV9Pk9LpE (Twitter) - Jun 14, 2023
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda. (Pubmed Central) - Jun 13, 2023
However, they felt the health system could overcome these challenges. Implementation complexities must be addressed as LAI ART is introduced and expanded in Africa to best support viral suppression and address HIV care continuum gaps.
- |||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P3 trial, Patient reported outcomes: Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (clinicaltrials.gov) - Jun 9, 2023
P3, N=93, Active, not recruiting, Sponsor: ViiV Healthcare
- |||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P3 trial: A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants (clinicaltrials.gov) - Jun 9, 2023
P3, N=118, Completed, Sponsor: ViiV Healthcare
- ||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - May 10, 2023
P3, N=688, Completed, Sponsor: ViiV Healthcare
Implementation complexities must be addressed as LAI ART is introduced and expanded in Africa to best support viral suppression and address HIV care continuum gaps. Active, not recruiting --> Completed
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Association of oral lead-in and persistence on cabotegravir and rilpivirine long-acting in () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1534;
Active, not recruiting --> Completed Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the Phase 3b SOLAR study () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1497;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS study () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1361;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b SOLAR study (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_465;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the Phase 3b SOLAR study (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_464;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Optimizing the clinic flow process for integration of cabotegravir + rilpivirine long-acting into routine care: findings from Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_264;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Barriers and facilitators to the implementation of Cabotegravir + Rilpivirine long-acting injectable HIV treatment among healthcare providers: baseline qualitative findings from the ILANA study (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_258;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- |||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New trial, HEOR: CABO-LA: Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (clinicaltrials.gov) - Apr 28, 2023
P=N/A, N=50, Not yet recruiting, Sponsor: Pontificia Universidad Catolica de Chile